Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma
Journal of Clinical Oncology · 2026-02 · 44 (4) · 321-334
DOI: 10.1200/jco-25-00289 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2026-02. Verfasst von Anil Aktas Samur und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA. Hauptthemen laut MEDLINE: Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE The diagnosis of smoldering multiple myeloma (SMM) primarily relies on clinical features such as plasma cell involvement, immunoglobulin protein levels, and end-organ damage. However, as early intervention becomes a priority, the role of genomic features in differentiating risk is gaining attention. METHODS This study analyzed next-generation sequencing data from 224 precursor condition samples with 51 patients having paired SMM and multiple myeloma (MM) and 1,779 samples from newly diagnosed MM to identify genomic features linked to progression in SMM and those with a low-risk nonprogressor precursor condition. RESULTS Our findings from paired samples revealed no significant differences in somatic alterations and clonal structures between SMM and MM samples from the same patient. This indicates that plasma cells in progressor SMM are genomically pre-equipped with changes that define myeloma. Over 80% of driver mutations were present at both time points, and more than 66% of progressor samples showed only minor clonal changes. We further compared genomic changes between nonprogressor and progressor SMM. Nonprogressor plasma cells showed significantly lower mutational load and the absence of copy number alterations on chromosome 8. They reduced focal genomic loss compared with progressor plasma cells. A scoring system using genomic features predictively identified patients with low-risk SMM unlikely to progress, validated on 101 additional independent samples, and additive clinical value of genomic classification was further shown in combination with 20/2/20. CONCLUSION In summary, the genomic distinctions now suggest that a proportion of SMMs with progressor phenotype are akin to MM, whereas nonprogressor SMM has monoclonal gammopathy of undetermined significance–like characteristics. The results should influence further investigation in larger studies to inform future diagnostic criteria and trial designs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA.
- University Cancer Center of Toulouse Institut National de la Santé, Toulouse, France.
- Genome Informatics, Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH.
- Department of Data Science, Dana Farber Cancer Institute, Boston, MA.
- Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA.
- Department of Hematology and Medical Oncology, Boston University Medical Center, Boston, MA.
ORCID-Profile: Anil Aktas Samur, Jill Corre, Joshua Rivera, Yiyang Fan, Bahar Dakiki Korucu, Mariateresa Fulciniti, Kenneth C Anderson, Adam Sperling, Giovanni Parmigiani, Hervé Avet-Loiseau, Nikhil C Munshi, Mehmet Kemal Samur
Förderung
- NCI NIH HHS
Zitieren
APA
Aktas Samur, A., Corre, J., Talluri, S., Shah, P., Graffeuil, A., Rivera, J., Fan, Y., Dakiki Korucu, B., Szalat, R., Fulciniti, M., Anderson, K. C., Sperling, A., Parmigiani, G., Avet-Loiseau, H., Munshi, N. C., & Samur, M. K. (2026). Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma. Journal of Clinical Oncology, 44(4), 321-334. https://doi.org/10.1200/jco-25-00289
Vancouver
Aktas Samur A, Corre J, Talluri S, Shah P, Graffeuil A, Rivera J, et al. Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma. Journal of Clinical Oncology. 2026;44(4):321-334. doi:10.1200/jco-25-00289
BibTeX
@article{AktasSamur2026,
author = {Aktas Samur, Anil and Corre, Jill and Talluri, Srikanth and Shah, Parth and Graffeuil, Antoine and Rivera, Joshua and Fan, Yiyang and Dakiki Korucu, Bahar and Szalat, Raphael and Fulciniti, Mariateresa and Anderson, Kenneth C and Sperling, Adam and Parmigiani, Giovanni and Avet-Loiseau, Hervé and Munshi, Nikhil C and Samur, Mehmet Kemal},
title = {Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {4},
pages = {321--334},
doi = {10.1200/jco-25-00289}
}
EUVIMED